Midatech Pharma Share Price (MTPH)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Midatech Pharma	LSE:MTPH	London	Ordinary Share	GB00BRTL9B63	ORD 0.005P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-2.50p	-3.29%	73.50p	73.00p	74.00p	76.00p	73.50p	76.00p	3,077	13:11:15

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	6.9	-29.3	-56.0	-	35.81

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Port Erin (PEBI), Valirx (VAL)

Midatech Pharma (MTPH) Latest News

Midatech Pharma News

Date	Time	Source	Headline
21/9/2017	09:00	UKREG	Midatech Pharma PLC Holding(s) in Company
07/9/2017	07:01	UKREG	Midatech Pharma PLC Notice of interim results
04/9/2017	11:48	ALNC	Midatech Pharma Submits Clinical Trial Application For MTD201
04/9/2017	07:27	ALNCF	Alliance News Flash Headline
04/9/2017	07:00	UKREG	Midatech Pharma PLC Midatech submits MTD201 CTA filing
25/8/2017	13:59	UKREG	Midatech Pharma PLC Holding(s) in Company
26/7/2017	13:05	ALNC	Midatech Pharma Gets Good Results For MTD119 In Liver Cancer Study
26/7/2017	07:01	RNSNON	Midatech Pharma PLC Completion of pre-clinical liver cancer programme
18/7/2017	11:32	ALNC	Midatech Pharma On-Track With Expected Interim Revenue Rise
18/7/2017	07:01	UKREG	Midatech Pharma PLC Trading Update and Notice of Results

More Midatech Pharma News

Midatech Pharma Takeover Rumours

Midatech Pharma (MTPH) Share Charts

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

Intraday Midatech Pharma Chart

Midatech Pharma (MTPH) Discussions and Chat

Midatech Pharma Forums and Chat

Date	Time	Title	Posts
26/7/2017	08:36	Midatech Pharma (MTPH) sees 10-fold increase	60
03/1/2017	12:41	Midatech Pharma PLC	181
10/8/2016	08:55	MTPH	-

Add a New Thread

Midatech Pharma (MTPH) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Midatech Pharma trades in real-time

Midatech Pharma (MTPH) Top Chat Posts

Date	Subject
24/9/2017 09:20	Midatech Pharma Daily Update: Midatech Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker MTPH. The last closing price for Midatech Pharma was 76p. Midatech Pharma has a 4 week average price of 70p and a 12 week average price of 70p. The 1 year high share price is 152.50p while the 1 year low share price is currently 70p. There are currently 48,719,456 shares in issue and the average daily traded volume is 15,245 shares. The market capitalisation of Midatech Pharma is £35,808,800.16. Read Full Thread Reply
05/4/2017 13:57	jamtomorrow2: Loss of £20m and one failed drug and a share price down 50%. A really great year! Read Full Thread Follow Reply
26/4/2016 12:47	thomasthetank1: Read Panmure Gordon & Co's note on MIDATECH PHARMA, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BRTL9B63 "More good news this morning. Positive pharmacokinetic data from Midatech’s Q-Octreotide programme (MTD201) for the treatment of acromegaly and carcinoid syndrome demonstrate a favourable profile against the reference and market leader Sandostatin LAR Depot (Novartis). This paves the way towards IND submission and bio-equivalence in human studies expected in late 2016 and today’s news adds further weight and momentum to the company’s recent news flow. With significant headroom on the current share price ..." Read Full Thread Follow Reply
13/4/2016 12:33	thomasthetank1: Read Panmure's note on Midatech Pharma (MTPH), out this morning, by visiting www.research-tree.com … “Today’s FY15 results see revenues of £1.38m ahead of our expectations (PGe £1.30m, 2014: £0.16m) and, adjusting for one-off listing/acquisition items, the strong performance is also reflected at the bottom-line, with adjusted pre-tax loss of £9.9m vs PGe £10.6m loss. Delivery of this kind, during a period of high activity, reflects well on management capabilities and bandwidth. The parallel strands of commercial and pipeline development bode well for the long-term risk and growth profile of the business and we note strong revenues from marketed products in the first three months of 2016 with trading ‘slightly ahead of market expectations’. We retain our earnings forecasts unchanged for now but will look to future updates with respect to potential headroom on our forecasts. In the meantime, our view remains that there is significant headroom on the current share price…” Read Full Thread Follow Reply
13/3/2016 19:47	hutch_pod: Good interview. Liked hearing his view on the share price and Dara shareholder profit taking. Hope April delivers good progress. Read Full Thread Follow Reply
30/12/2015 09:57	hutch_pod: Did you see this from 17th? hTtp://seekingalpha.com/author/bart-van-velzen/comments High time for an update on this article: the merger has been approved, the ADR's have been issued, but the idea so far hasn't worked out like I had planned. One of the risks highlighted in the article was: "Midatech's ADRs trading in tandem with its Ordinary Shares could cause the price of the ADRs to go up, but the same mechanism could obviously also cause the price of the Ordinary Shares in the UK to go down." Unfortunately, this is what happened. Since the deal was completed the MTPH share price in London took a bath and has now dropped close to 25% in about two weeks, making this deal a nightmare for the UK holders. I indicated in the article MTPH was illiquid and unshortable; I knew the shares in London would likely drop as a result of ADR-holders converting and selling, explaining some of the premium to the US price. But I hadn't expected an <20M take over to cause MTPH to shed >30M in market cap which in itself is of course fundamentally questionable; Midatech + DARA combined is now worth less than Midatech itself used to do. Also, trading volumes were horrendously low. I had expected MTPH-management, or any of its many experienced institutional investors, to see this coming based on the illiquidity of MTPH-shares, and to have at least something of contingency plan ready. Apparently so far they didn't. One would assume experienced investors like Neil Woodford (who holds an 18% stake through Woodford Investment Management) would not allow his fund to lose millions in a few days on trading volumes of about 40K $ without stepping in. One would also assume he, or any one of the other holders being hung out to dry, still will. It wouldn't take much. Anyway, with regards to ADR conversion: no US listed ADR I'm aware of trades at a discount to its UK listed peers, and MTP won't either in the mid term Read Full Thread Follow Reply
18/12/2015 15:56	njw2: The problem is quite simple, there is a major seller in the US line ( probably someone being stopped out from the total bulls up with the confusion on the merger )and until this is dealt with the share price collapse will continue. Maybe if someone at the company had a brain they would find the seller and take him out. Until that happens the share price will continue to collapse and there is no bottom on this. Read Full Thread Follow Reply
18/12/2015 12:07	deltrotter: They could well be in a closed period though tools with further news pending. The trading update in Q1 should make very interesting reading. I am peeved with the share price and their investor relations, but I am not peeved with their strategy and the execution of it. Read Full Thread Follow Reply

Midatech Pharma share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:43 V: D:20170924 14:09:43